Identified cause of Uveitis | Number (Percentage) | Age (years) | Gender (M:F) | Anatomical Localization (Ratio, %) | Time from Diagnosis to Rituximab Treatment (months) | Rituximab Regimen (Ratio, %) | Positive Therapeutic Response (Ratio, %) | Recurrence (Ratio, %) | Adverse Events (Ratio, %) |
---|---|---|---|---|---|---|---|---|---|
Non-paraneoplastic autoimmune retinopathy | 30 (28.0%) | Mean: 50.7 ± 16.7 Median: 52.5 Range: 10.0–75.0 | 0.25:1 | Posterior uveitis (30/30, 100%) | Mean: 18.4 Median: 15.0 Range: 2.0–48.0 | Rheumatologic (7/30, 23.3%); Oncologic (3/30, 10.0%); Foster (6/30, 20.0%); Other (5/30, 16.7%); Rheumatologic or oncologic (9/30, 30.0%) | 24/30, 80.0% | 1/24, 4.2% | None (17/26, 65.4%); Unspecified infusion reaction (4/26, 15.4%); Sinusitis (1/26, 7.7%); Infusion reaction with tachycardia (1/26, 3.8%); Leukopenia (1/26, 3.8%); unspecified dermatitis (1/26, 3.8%); Sinusitis, Herpes zoster, nodular scleritis (1/26, 3.8%) |
Juvenile idiopathic arthritis | 21 (19.6%) | Mean: 20.7 ± 5.7 Median: 21.0 Range: 13.0–34.0 | 0.12:1 | Anterior uveitis (18/21, 85.7%); Unspecified uveitis (2/21, 9.5%); Anterior and intermediate uveitis (1/21, 4.8%); | Mean: 48.0Median: 36.0 Range: 24.0–168.0 | Rheumatologic (11/21, 52.4%); Two infusions of 375 mg/m2 separated by 2 weeks (10/21, 47.6%) | 16/21, 76.2% | 11/16, 68.8% | None (21/21, 100%) |
Vogt-Koyanagi-Harada disease | 12 (11.2%) | Mean: 23.4 ± 10.8 Median: 21.0 Range: 8.0–41.0 | 100% F | Anterior uveitis (8/11, 72.7%); Panuveitis (3/11, 27.3%) | Mean: 49.5 Median: 36.0 Range: 10.0–156.0 | Rheumatologic (8/12, 66.7%); Other (4/12, 33.3%) | 12/12, 100% | 0/12, 0% | None (10/10, 100%) |
Behcet’s disease | 11 (10.3%) | Mean: 28.8 ± 10.7 Median: 28.0 Range: 17.0–51.0 | 1.75:1 | Posterior uveitis (11/11, 100%) | NR | Rheumatologic (11/11, 100%) | 11/11, 100% | 10/11, 90.9%b | None (6/11, 54.5%); Conjunctivitis (2/11, 18.2%); Pneumonia (1/11, 9.1%); Herpes zoster (1/11, 9.1%); Flushing (1/11, 9.1%); Mild urticaria (1/11, 9.1%) |
Cancer-associated and Melanoma-associated retinopathy | 11 (10.3%)a | Mean: 63.3 ± 13.5 Median: 61.0 Range: 46.0–86.0 | 0.38:1 | Posterior Uveitis (11/11, 100%) | Mean: 19.1 Median: 12.5 Range: 0–75.0 | Either rheumatologic or oncologic protocol (9/11, 81.8%); Unspecified (2/11, 18.2%) | 6/11, 54.5% | N/A | None (6/8, 75%); Infusion reaction (2/8, 25%) |
Sarcoidosis | 4 (3.7%) | Mean: 47.75 Median: 47.5 Range: 46.0–50.0 | 100% F | Panuveitis (3/4, 75.0%) Unspecified uveitis (1/4, 25.0%) | NR | Rheumatologic (4/4, 100%) | 3/4, 75.0% | NR | Neutropenia (2/4, 50.0%); Staphylococcus aureus skin infections (1/4, 25.0%); None (1/4, 25.0%) |
Otherc | 9 (8.4%) | Mean: 48.0 ± 9.6 Median: 42.0 Range: 37.0–62.0 | 0.5:1 | Posterior uveitis (3/9, 33.3%); Panuveitis (2/9, 22.2%); Anterior uveitis (1/9, 11.1%); Anterior and intermediate uveitis (1/9, 11.1%); Anterior uveitis and vasculitis (1/9, 11.1%); Unspecified uveitis and vasculitis (1/9, 11.1%) | NR | Rheumatologic (3/8, 37.5%); Foster (4/8, 50.0%); Other (1/8, 12.5%) | 5/5, 100% | 1/5, 20.0% | None (3/3, 100%) |
Indeterminate | 9 (8.4%) | Mean: 43.2 ± 19.0 Median: 49.0 Range: 14.0–65.0 | 0.13:1 | Panuveitis (5/9, 55.6%); Posterior uveitis (2/9, 22.2%); Anterior uveitis (2/9, 22.2%) | NR | Foster(7/9, 77.8%); Rheumatologic (1/9, 11.1%); Oncologic (1/9, 11.1%) | 4/4, 100% | 1/4, 25% | None (1/3, 33.3%); Fungal skin infection (1/3, 33.3%); Gastrointestinal discomfort (1/3, 33.3%) |